These final results, together with a former report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,2 aid the idea of concentrating on ACKR3 as a novel solution to modulate the opioid process, which could open up new therapeutic avenues for opioid-similar disorders.At that time, Microsoft Promoting w